大规模多组分干预减少质子泵抑制剂过度使用的效果:整合医疗系统中的双重差分研究
该双重差分研究在美国退伍军人医疗系统开展,一个区域网络实施以减少PPI过度使用为目标的多组分药房干预(限制无长期使用指征者的PPI续配、作废近期未填充的PPI处方、促进H2受体拮抗剂电子处方、对患者和临床医生教育),其余17个网络作为对照,纳入2009至2019年所有接受初级保健的个体。干预与PPI处方填充率绝对降低7.3%(95%CI -7.6%至-7.0%)相关,在适用于胃保护的患者中PPI使用绝对降低11.3%(95%CI -12.0%至-10.5%),PPI或H2受体拮抗剂处方填充绝对降低5.72%(95%CI -6.08%至-5.36%)。上消化道诊断的初级保健就诊、上消化道内镜、适合胃保护的老年患者酸消化性疾病住院均未增加,任何PPI相关临床状况未见有临床意义的变化。结论认为该干预与PPI总体使用减少相关,但适用于胃保护的患者中PPI使用也减少,临床获益或危害证据极少。
要点
- 干预与PPI处方填充绝对减少7.3%(95%CI -7.6%至-7.0%)相关,但适用于胃保护的患者PPI使用也绝对减少11.3%(95%CI -12.0%至-10.5%)。
- 干预与PPI或H2受体拮抗剂处方填充绝对减少5.72%(95%CI -6.08%至-5.36%)相关。
- 上消化道诊断的初级保健就诊、上消化道内镜、适合胃保护的老年患者酸消化性疾病住院均未增加。
- 任何PPI相关临床状况均未见有临床意义的变化。
- 干预前26%的患者在接受PPI;干预包括限制无长期使用指征者的PPI续配、作废近期未填充的PPI处方、促进H2受体拮抗剂电子处方、对患者和临床医生教育。
适用人群与场景
- 2009至2019年在美国退伍军人医疗系统接受初级保健的所有个体;干预区域网络每区间分析192 607至250 349例,对照区域网络每区间分析3 775 953至4 360 868例。
处置流程与药物剂量
- 干预措施包括:对无长期使用指征记录的患者限制PPI续配;作废近期未填充的PPI处方;促进H2受体拮抗剂的电子处方;对患者和临床医生进行教育。
研究设计与关键结果
- 研究设计为双重差分研究,设置于美国退伍军人医疗系统,一个区域网络实施减少PPI过度使用的干预,其余17个网络作为对照,纳入2009至2019年所有接受初级保健的个体。
- 主要结局为每6个月填充PPI处方的患者百分比;干预与绝对降低7.3%(95%CI -7.6%至-7.0%)相关。
- 在适用于胃保护的患者中,PPI使用绝对降低11.3%(95%CI -12.0%至-10.5%)。
- 填充PPI或H2受体拮抗剂处方的患者百分比绝对降低5.72%(95%CI -6.08%至-5.36%)。
- 上消化道诊断的初级保健就诊、上消化道内镜、适合胃保护的老年患者酸消化性疾病住院均未增加。
- 任何PPI相关临床状况均未见有临床意义的变化。
证据类型、等级与局限
- 证据类型:双重差分研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该多组分药房干预与PPI总体使用减少相关,但适用于胃保护的患者中PPI使用也减少,临床获益或危害证据极少;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine how a large scale, multicomponent, pharmacy based intervention to reduce proton pump inhibitor (PPI) overuse affected prescribing patterns, healthcare utilization, and clinical outcomes.
DESIGN: Difference-in-difference study.
SETTING: US Veterans Affairs Healthcare System, in which one regional network implemented the overuse intervention and all 17 others served as controls.
PARTICIPANTS: All individuals receiving primary care from 2009 to 2019.
INTERVENTION: Limits on PPI refills for patients without a documented indication for long term use, voiding of PPI prescriptions not recently filled, facilitated electronic prescribing of H2 receptor antagonists, and education for patients and clinicians.
MAIN OUTCOME MEASURES: The primary outcome was the percentage of patients who filled a PPI prescription per 6 months. Secondary outcomes included percentage of days PPI gastroprotection was prescribed in patients at high risk for upper gastrointestinal bleeding, percentage of patients who filled either a PPI or H2 receptor antagonist prescription, hospital admission for acid peptic disease in older adults appropriate for PPI gastroprotection, primary care visits for an upper gastrointestinal diagnosis, upper endoscopies, and PPI associated clinical conditions.
RESULTS: The number of patients analyzed per interval ranged from 192 607 to 250 349 in intervention sites and from 3 775 953 to 4 360 868 in control sites, with 26% of patients receiving PPIs before the intervention. The intervention was associated with an absolute reduction of 7.3% (95% confidence interval -7.6% to -7.0%) in patients who filled PPI prescriptions, an absolute reduction of 11.3% (-12.0% to -10.5%) in PPI use among patients appropriate for gastroprotection, and an absolute reduction of 5.72% (-6.08% to -5.36%) in patients who filled a PPI or H2 receptor antagonist prescription. No increases were seen in primary care visits for upper gastrointestinal diagnoses, upper endoscopies, or hospital admissions for acid peptic disease in older patients appropriate for gastroprotection. No clinically significant changes were seen in any PPI associated clinical conditions.
CONCLUSIONS: The multicomponent intervention was associated with reduced PPI use overall but also in patients appropriate for gastroprotection, with minimal evidence of either clinical benefits or harms.
参考来源
- Kurlander JE, Laine L, Kim HM, et al. Impact of large scale, multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system: difference-in-difference study. BMJ. 2024. PMID: 38604668. doi:10.1136/bmj-2023-076484
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。